Cargando…

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review

PURPOSE: Mutations in the genes BRCA1 and BRCA2 represent a significant risk factor for ovarian and breast cancer. With increasing number and success rates, fertility protection and treatment are gaining importance also for BRCA1/2 mutation carriers. However, the effect on primary cancer risk and ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huber, D., Seitz, S., Kast, K., Emons, G., Ortmann, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447664/ https://www.ncbi.nlm.nih.gov/pubmed/32719921 http://dx.doi.org/10.1007/s00404-020-05690-4

Ejemplares similares

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2021)

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2020)

Correction to: Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2021)

The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy
por: Markowska, J., et al.
Publicado: (2013)

Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors
por: Wang, Lifei, et al.
Publicado: (2022)

Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT
por: von Wolff, Michael, et al.
Publicado: (2011)

Perspectives of Young Women With Gynecologic Cancers on Fertility and Fertility Preservation: A Systematic Review
por: Gonçalves, Vânia, et al.
Publicado: (2022)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
por: Grill, Sabine, et al.
Publicado: (2020)

Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: Can One Still Effectively Become a Mother? A Systematic Review of Fertility Outcomes
por: Ronsini, Carlo, et al.
Publicado: (2023)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Mucinous borderline ovarian tumors with BRAF(V600E) mutation may have low risk for progression to invasive carcinomas
por: Ohnishi, Kaori, et al.
Publicado: (2020)

Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center
por: Zang, Benedikt, et al.
Publicado: (2022)

Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients
por: Taubenhansl, Clara, et al.
Publicado: (2019)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Impact of cavity shaving on residual tumor rates in patients with primary invasive carcinoma and carcinoma in situ in breast conserving surgery
por: Fernández-Pacheco, Miriam, et al.
Publicado: (2022)

Regression of Acoustic Tumor After Chemotherapy for Ovarian Cancer in a Patient With a Breast Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation
por: Takeda, Anna, et al.
Publicado: (2023)

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue
por: Peters, Inge T. A., et al.
Publicado: (2016)

Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances—A Systematic Review of Oncological Outcomes
por: Ronsini, Carlo, et al.
Publicado: (2022)

The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group
por: Hasenburg, Annette, et al.
Publicado: (2021)

Autologous fat grafting for breast reconstruction after breast cancer: a 12-year experience
por: Kempa, Sally, et al.
Publicado: (2021)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
por: Kuchenbaecker, Karoline B., et al.
Publicado: (2017)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

Overview on population screening for carriers with germline BRCA mutation in China
por: Lei, Huijun, et al.
Publicado: (2022)

Health Disparities in Ovarian Cancer: Report From the Ovarian Cancer Evidence Review Conference
por: Mei, Shirley, et al.
Publicado: (2023)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk
por: Kwiatkowski, Fabrice, et al.
Publicado: (2015)

The effect of radiotherapy on fat engraftment for complete breast reconstruction using lipofilling only
por: Heine, Norbert, et al.
Publicado: (2022)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center
por: Loehberg, Christian R., et al.
Publicado: (2020)

Prostatic tissue: an unexpected finding in a mature ovarian teratoma: Case report and systematic literature review
por: Pecorella, Irene, et al.
Publicado: (2021)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience
por: Costantini, Barbara, et al.
Publicado: (2022)

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers
por: Tommasi, Chiara, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review
por: Li, Jiaxin, et al.
Publicado: (2022)

Executive Summary of the Ovarian Cancer Evidence Review Conference
por: Burke, William, et al.
Publicado: (2023)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_32qd33q3uf0u7s6pm1o8smet6j